Learn more at MyFlarex.com
By balancing efficacy and safety, you can tailor
treatment to meet the exact needs of your patients
1
•
Superior efficacy vs FML
®
(fluorometholone
ophthalmic suspension, USP) 0.1%*
2,a
•
Similar efficacy to prednisolone acetate 1.0%
2,a
•
No differences in adverse reactions vs FML*
and prednisolone acetate 1.0%
2,a
•
The lowest-cost branded corticosteroid
3,b
•
No generic equivalent—prescribe FLAREX by name
4
INDICATIONS AND USAGE
FLAREX
®
(fluorometholone acetate ophthalmic suspension) is indicated for use in the treatment of steroid-responsive
inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Contraindicated in acute superficial herpes simplex keratitis, vaccinia, varicella, and most other viral diseases
of the cornea and conjunctiva; mycobacterial infection of the eye; fungal diseases; acute purulent untreated
infections, which like other diseases caused by microorganisms, may be masked or enhanced by the presence
of the steroid; and in those persons who have known hypersensitivity to any component of this preparation.
Please see brief summary of Full Prescribing Information on the adjacent page.
a
STUDY DESIGN: The efficacy and safety of FLAREX (n=41) vs FML* (n=37) were evaluated in a randomized,
double-blind clinical trial in 78 patients with ocular surface inflammation (eg, conjunctivitis, episcleritis, scleritis)
in one or both eyes. In a separate randomized, double-blind clinical trial in 82 patients with ocular surface
inflammation in one or both eyes, the efficacy and safety of FLAREX (n=37) vs prednisolone acetate 1.0% (n=45)
were evaluated. In these studies, patients administered either FLAREX or FML*/prednisolone acetate 1.0% every
2 hours for the first 2 days and then every 4 hours thereafter, with signs and symptoms of inflammation assessed
at Days 1, 3, 8, and 13. At each visit, investigators determined if symptoms in the involved eye were resolved
(cured), improved, unchanged, or worsened. If a patient was rated as cured before the end of the study, steroid
drops were discontinued and the patient was considered to have completed the trial.
2
b
Cost information based on Wholesale Acquisition Cost (WAC), 2019 data.
PRECISION POTENCY
FLAREX
®
provides the precise level of potency
when treating ocular surface inflammation
1,2
© 2019 Eyevance Pharmaceuticals LLC. All rights reserved.
FLAREX
®
is a registered trademark of Alcon Research, Ltd.
*All other trademarks are the property of their respective owners.
FLA-09-19-AD-43
